Diversity initiatives sits at the center of this dementia and brain health question.
Diversity initiatives are actively working to close significant gaps in Alzheimer’s care access, though the challenge is urgent and the disparities profound. Black Americans develop Alzheimer’s disease at twice the rate of non-Hispanic Whites, while Hispanic and Latino adults develop it at 1.5 times the rate—disparities rooted in genetics, cumulative health inequities, and limited access to quality diagnostic and preventive care. These initiatives are responding to a demographic reality: by 2030, nearly 40% of all Americans living with Alzheimer’s will be Black or Latino, yet these communities remain dramatically underrepresented in research, underdiagnosed by healthcare systems, and underserved by treatment options. Organizations ranging from the Alzheimer’s Association to the National Institute on Aging are launching community health engagement hubs, funding culturally tailored outreach programs, and expanding research partnerships with historically marginalized communities to ensure that tomorrow’s treatments benefit everyone who needs them, not just those from well-resourced populations.
The goal of these initiatives is clear: close the enormous disparities in diagnosis, access to clinical trials, and treatment uptake. However, the barriers are structural and deep. Healthcare provider shortages in communities of color, decades of medical mistrust rooted in real historical wrongs, language barriers, and a research enterprise that historically excluded minorities all contribute to the current gaps. This article examines the scale of these disparities, why they exist, what evidence-based solutions are being deployed, and what still needs to happen to ensure equitable Alzheimer’s care for all communities.
Table of Contents
- Why Alzheimer’s Disparities Persist Across Racial and Ethnic Communities
- The Research Participation Crisis and What It Means for Future Treatments
- The Growing Economic Burden of Unaddressed Disparities
- What Diversity Initiatives Are Doing Now
- The Trust Barrier and Why Provider-Community Relationships Matter
- Community Health Workers and Trusted Messengers
- Building Toward Equitable Outcomes and the Road Ahead
- Conclusion
- Frequently Asked Questions
Why Alzheimer’s Disparities Persist Across Racial and Ethnic Communities
The health disparities in Alzheimer’s disease are not random or inevitable—they reflect longstanding inequities in access to cardiovascular care, diabetes management, education, and preventive health services. Black Americans and Hispanic/Latino adults face higher rates of hypertension, diabetes, and cardiovascular disease, all established risk factors for cognitive decline and dementia. Beyond biology, they encounter systemic barriers: fewer specialists in majority-minority neighborhoods, longer waits for appointments, less time with doctors during visits, and provider biases that can result in symptoms being dismissed or attributed to normal aging rather than investigated as potential dementia.
A critical gap emerges at the diagnostic stage. research from UC Davis Health shows that minoritized populations are significantly less likely to receive an accurate or timely dementia diagnosis and are prescribed anti-dementia medications like cholinesterase inhibitors at lower rates than White populations. This means that Black and Latino adults with early cognitive impairment often go undiagnosed until symptoms are severe, missing the window when disease-modifying treatments might slow progression. Trust compounds the problem: fewer than 50% of Black Americans and Native Americans feel confident they have access to healthcare providers who understand their ethnic and racial background, and Black Americans are twice as likely as other groups to say they distrust medical research—a legacy of the Tuskegee experiments and other documented harms.
The Research Participation Crisis and What It Means for Future Treatments
Alzheimer’s research has historically reflected and reinforced disparities. Between 2000 and 2019, 90% of completed Alzheimer’s clinical trials had 75% to 100% non-Hispanic White participants, and today non-White participation in Alzheimer’s trials remains below 10%. This underrepresentation has profound implications: medications and therapies are developed and tested primarily on White populations, meaning their efficacy, optimal dosing, and side effects in Black and Latino populations remain unknown. A drug that works for one population may perform differently in another due to genetic differences, differences in disease biology, or differences in how medications are metabolized.
However, recent research from Emory University (published January 2026) offers a concrete pathway forward. Emory researchers identified effective strategies to increase diversity in Alzheimer’s research through intentional outreach and partnerships with trusted community organizations. Rather than expecting patients to come to research centers, successful programs bring researchers to trusted community institutions—churches, senior centers, community health centers—and work with community liaisons who have existing relationships and credibility. This approach has demonstrably increased African American participation in Alzheimer’s research studies. The limitation is that scaling these programs requires sustained funding, training of community health workers, and commitment from institutions to do the harder work of genuine partnership rather than surface-level recruitment.
The Growing Economic Burden of Unaddressed Disparities
The economic cost of these disparities is staggering and accelerating. In 2020, the combined economic burden of Alzheimer’s and related dementias (ADRD) for African American and Latino communities was $113 billion—but this number is projected to reach $1.7 trillion by 2060. For the Latino community alone, the cumulative economic impact is projected to reach $2.35 trillion by 2060. These figures include direct medical costs (hospitalizations, medications, care services), lost productivity from caregiver burden, and informal caregiving expenses that disproportionately fall on families and communities with fewer financial resources.
What makes these projections particularly urgent is that they are largely preventable. If Black and Latino Americans received the same level of early diagnosis, access to disease-modifying treatments, and preventive care as White populations, cognitive decline could be slowed or prevented in many cases. Instead, later diagnosis often means more rapid progression, higher care intensity, and greater economic burden on individuals and families. The economic disparities also create a cruel feedback loop: communities bearing the heaviest disease burden often have the fewest resources to invest in prevention and early intervention, widening the gap further with each passing decade.
What Diversity Initiatives Are Doing Now
The Alzheimer’s Association launched its Health Equity Impact Report in 2026, which establishes a concrete agenda for change. The initiative includes establishing community health engagement hubs in metropolitan areas where dementia rates are highest among Black and Hispanic populations. These hubs are designed to serve as trusted resources—places where community members can get screening, education, and connections to care without navigating a complex and often unwelcoming healthcare system. The Association is also developing replicable models for increasing Black and Hispanic American engagement in dementia clinical research, moving away from a model of “come to our research center” toward community-embedded approaches.
The National Institute on Aging has made dementia research diversity a priority in its FY2026 budget, with explicit focus on engaging historically underrepresented communities in research. The NIH is funding studies that examine not just disease burden but also which interventions work in specific populations. This represents a significant shift—previously, many researchers assumed that treatments effective in predominantly White populations would work the same way universally. Now the emphasis is on designing studies that include diverse populations from the start and that measure health outcomes across racial and ethnic subgroups. Additionally, diversity initiatives are expanding internationally; Alzheimer’s Research UK is extending similar programs into Black African and Black Caribbean communities in East London, recognizing that health disparities in dementia extend beyond the United States.
The Trust Barrier and Why Provider-Community Relationships Matter
Even well-designed programs cannot succeed without trust, and trust in healthcare institutions among Black and Latino Americans is hard-earned and fragile. Medical racism is not historical—it is ongoing and documented. Studies show that Black patients receive less pain medication for the same conditions, that implicit bias affects clinical decision-making, and that providers often make assumptions about patients’ compliance, intelligence, and health beliefs based on race.
Building trust requires more than implicit bias training; it requires structural changes in hiring and retention of providers from underrepresented backgrounds, cultural competency training that goes beyond a single workshop, and accountability when discrimination occurs. A critical limitation of many current diversity initiatives is that they focus on increasing participation in existing systems rather than transforming those systems to be genuinely culturally humble and responsive. If a Black patient participates in a clinical trial at a hospital where they’ve experienced dismissal or discrimination before, recruitment numbers will not translate into retention or engagement. Successful programs combine research excellence with genuine cultural respect—employing community health workers from the communities served, creating community advisory boards with real decision-making power, and being willing to modify research protocols or care delivery models based on community feedback.
Community Health Workers and Trusted Messengers
One of the most effective strategies emerging from diversity initiatives is the deliberate deployment of community health workers (CHWs) and community liaisons. These are individuals from the same communities served—often with lived experience of dementia themselves, either personally or through family—who serve as trusted messengers and bridges between healthcare institutions and their communities. In neighborhoods where many people have negative experiences with healthcare, a CHW can explain what a research study entails, address specific concerns, and provide continuity of relationship and support throughout a patient’s participation.
The Emory research showing increased diversity in Alzheimer’s trials specifically attributed success to partnerships with community organizations and the employment of community liaisons. However, the scalability challenge is real: community health workers are often underpaid, their contributions undervalued, and their positions precarious. For diversity initiatives to be sustainable, they must invest in training and career pathways for community health workers, not treat them as temporary grant-funded positions.
Building Toward Equitable Outcomes and the Road Ahead
The initiatives underway in 2026 represent a meaningful shift toward equity in Alzheimer’s care, but they are early and fragile. The expansion of community health engagement hubs, the increased funding for diversity in research, and the evidence from Emory and other institutions showing that intentional outreach works are all hopeful developments. Yet hope without sustained commitment and funding is insufficient. The projected economic burden of $1.7 trillion for African American ADRD and $2.35 trillion for Latino ADRD by 2060 will only materialize if we fail to act now; conversely, investments in equitable care and research today will pay dividends in prevented disease, earlier intervention, and better outcomes for millions of people.
The path forward requires both innovation and accountability. It means designing healthcare systems that are genuinely accessible—with providers who reflect the communities served, care delivered in trusted settings, and research that includes and benefits diverse populations. It means addressing the social determinants—poverty, neighborhood safety, food insecurity, educational access—that drive health disparities in the first place. And it means centering the voices and preferences of the communities most affected by Alzheimer’s in determining what equitable care looks like and how to get there.
Conclusion
Alzheimer’s disease does not strike all Americans equally. Black Americans develop the disease at twice the rate of White Americans, Hispanic and Latino adults at 1.5 times the rate, and by 2030 nearly 40% of Americans living with Alzheimer’s will be from these communities. Despite this burden, these same communities remain severely underrepresented in clinical research, less likely to receive timely diagnosis, and less likely to access disease-modifying treatments. This is not inevitable; it is a choice—a product of systems designed and maintained by decades of inequitable policies and practices. Diversity initiatives being deployed in 2026 and beyond are beginning to change this trajectory.
The Alzheimer’s Association’s community health engagement hubs, the NIH’s focus on underrepresented communities in dementia research, and the proven success of community-embedded approaches from Emory and other institutions all point toward what equitable Alzheimer’s care can look like. But these initiatives must be sustained and expanded, and they must be paired with structural reforms in healthcare access, provider diversity, and genuine community partnership. The stakes are enormous: $1.7 trillion in economic burden by 2060 for African American ADRD alone if we fail; and for millions of individuals and families, the difference between early diagnosis and intervention versus late-stage disease and irreversible decline. The science and the solutions exist. What is required now is the commitment to implement them equitably across all communities.
Frequently Asked Questions
Why do Black Americans and Hispanic/Latino Americans have higher rates of Alzheimer’s disease?
The disparities reflect a combination of factors: higher rates of cardiovascular disease, diabetes, and hypertension (established dementia risk factors); cumulative lifetime stress and discrimination; limited access to preventive care and health screenings; and environmental exposures in under-resourced neighborhoods. These are not genetic disadvantages but rather consequences of systemic health inequities that develop over a lifetime.
Why does it matter if Alzheimer’s research is predominantly White?
Treatments are developed and tested on the populations included in trials. If 90% of trial participants are White, medications and therapies are optimized for White populations, and their effectiveness and side effects in other populations remain unknown. This means Black and Latino patients taking FDA-approved Alzheimer’s drugs may experience different outcomes or adverse effects that were never studied.
What can patients do to ensure they have access to equitable Alzheimer’s care?
Ask for a referral to a neurologist or cognitive specialist, not just your primary care doctor, if you notice memory or thinking changes. Seek care at medical centers that participate in research diversity initiatives or community health programs. Bring a trusted family member or advocate to appointments. If you don’t feel heard by a provider, you have the right to seek a second opinion. Ask about clinical trials specifically recruiting from your community.
How long will it take for these diversity initiatives to show results?
Research recruitment and outcomes take years to measure. However, early indicators from Emory and other institutions show that community-embedded approaches can increase participation within one to two years. Full impact on treatment access and health outcomes will take longer—a decade or more—but the trends are measurable now.
What role do community health workers play in closing the care gap?
Community health workers serve as trusted messengers and bridges between healthcare systems and communities that have historically experienced medical racism or neglect. They can explain care options in language and contexts that resonate, address specific concerns rooted in real historical experiences, and provide continuity of support. Evidence shows they significantly increase both engagement in research and adherence to treatment.
Are there Alzheimer’s studies specifically recruiting diverse participants?
Yes. Many research centers and hospitals are now explicitly recruiting African American, Hispanic/Latino, Asian American, Native American, and other underrepresented populations for Alzheimer’s research. The Alzheimer’s Association, NIH, and individual medical centers can direct you to studies in your area. Look for programs that employ community health workers or community liaisons and that involve community advisory boards.
You Might Also Like
- Legal Cases Highlight Need for Better Alzheimer’s Care Oversight
- Collaborative Care Networks Enhance Alzheimer’s Treatment Delivery
- Caregiver Resources Expand as Alzheimer’s Patient Population Grows
For more, see Alzheimer’s Association — caregiving.
